Objectives On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir +ritonavir) asa treatment method that could reduce the risk of hospitalization or death for patients withconfirmed coronavirus disease 2019 (COVID-19).Methods: From February 6, 2022 to April 2, 2022, the incidence of COVID-19 and the effectsof treatment with Paxlovid were analyzed in 2,241 patients and workers at 5 long-term carefacilities during the outbreak of the Omicron variant of severe acute respiratory syndromecoronavirus 2 in South Korea.Results: The rate of severe illness or death in the group given Paxlovid was 51% lower thanthat of the non-Paxlovid group (adjusted risk ratio [aRR], 0.49; 95% confidence interval [CI],0.24−0.98). Compared to unvaccinated patients, patients who had completed 3 doses of thevaccine had a 71% reduced rate of severe illness or death (aRR, 0.29; 95% CI, 0.13−0.64) and a65% reduced death rate (aRR, 0.35; 95% CI, 0.15−0.79).Conclusion: Patients given Paxlovid showed a lower rate of severe illness or death and alower fatality rate than those who did not receive Paxlovid. Patients who received 3 dosesof the vaccine had a lower rate of severe illness or death and a lower fatality rate than theunvaccinated group.
Citations
Citations to this article as recorded by
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis Meital Zur, Thalia Peselev, Stav Yanko, Victoria Rotshild, Ilan Matok Antiviral Research.2024; 221: 105768. CrossRef
Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review Sydney Paltra, Tim O. F. Conrad Advances in Respiratory Medicine.2024; 92(1): 66. CrossRef
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis Sien Ombelet, Diego Castanares‐Zapatero, Fabian Desimpel, Frank Hulstaert, Sabine Stordeur, Dominique Roberfroid Journal of Medical Virology.2024;[Epub] CrossRef
Epidemiological evolution and economic impact of the COVID-19 pandemic in the European Union and worldwide and effects of control strategies on them: An ecological study J.A. Caylà, J.M. Bellmunt, J.M. Jansà, A. Marco, J.P. Millet Medicina de Familia. SEMERGEN.2024; 50(6): 102274. CrossRef
Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis Chienhsiu Huang, Sufang Kuo, Lichen Lin Tungs' Medical Journal.2024; 18(Suppl 1): S35. CrossRef
Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID‐19 patients with type 2 diabetes: A target trial emulation study Eric Y. F. Wan, Zoey C. T. Wong, Vincent K. C. Yan, Celine S. L. Chui, Francisco T. T. Lai, Xue Li, Ian C. K. Wong, Esther W. Y. Chan Diabetes, Obesity and Metabolism.2024; 26(10): 4653. CrossRef
COVID‐19 infection in patients with haematological malignancies: A single‐centre survey in the latest Omicron wave in China Xiaolu Zhu, Qian Jiang, Jin Lu, Yuqian Sun, Xiaosu Zhao, Shenmiao Yang, Feifei Tang, Wenjing Yu, Ting Zhao, Xiaohong Liu, Jinsong Jia, Wenbing Duan, Lijuan Hu, Jing Wang, Yang Liu, Nan Peng, Xuelin Dou, Rui Ma, Qiang Fu, Huifang Wang, Kaiyan Liu, Xiaojun British Journal of Haematology.2023; 202(1): 31. CrossRef
The association mental health of adolescents with economic impact during the COVID-19 pandemic: a 2020 Korean nationally representative survey Hanul Park, Kang-Sook Lee BMC Public Health.2023;[Epub] CrossRef
Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis Haokun Tian, Changsen Yang, Tiangang Song, Kechen Zhou, Lequan Wen, Ye Tian, Lirui Tang, Weikai Xu, Xinyuan Zhang Reviews in Medical Virology.2023;[Epub] CrossRef
Real-World Effectiveness of Nirmatrelvir-Ritonavir and Its Acceptability in High-Risk COVID-19 Patients Min-Kyung Kim, Kyung-Shin Lee, Sin Young Ham, Youn Young Choi, Eunyoung Lee, Seungjae Lee, Bora Lee, Jaehyun Jeon, BumSik Chin, Yeonjae Kim, Gayeon Kim, Hee-Chang Jang, Jae-Phil Choi, Sang-Won Park Journal of Korean Medical Science.2023;[Epub] CrossRef
Effectiveness of Molnupiravir Treatment in Patients with COVID-19 in Korea: A Propensity Score Matched Study Hye Rim Park, Min-Gyu Yoo, Jong Mu Kim, Soon Jong Bae, Hyungmin Lee, Jungyeon Kim Infection & Chemotherapy.2023; 55(4): 490. CrossRef
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19 Stefanie Reis, Maria-Inti Metzendorf, Rebecca Kuehn, Maria Popp, Ildiko Gagyor, Peter Kranke, Patrick Meybohm, Nicole Skoetz, Stephanie Weibel Cochrane Database of Systematic Reviews.2023;[Epub] CrossRef